In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

The efficacy and safety of simvastatin-fenofibrate fixed-dose combination in patients undergoing percutaneous coronary intervention

Session Oral abstract session: PPCI , risk factors and prevention

Speaker Bakhodir Narziev

Congress : EuroHeartCare 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes: Pharmacotherapy
  • Session type : Abstract Session
  • FP Number : 244

Authors : S Elmurodov (Tashkent,UZ), A Alyavi (Tashkent,UZ), B Narziev (Tashkent,UZ), A Madaliev (Tashkent,UZ)

Authors:
S Elmurodov1 , A Alyavi1 , B Narziev1 , A Madaliev1 , 1Tashkent Medical Academy, Cardiology - Tashkent - Uzbekistan ,

Citation:
European Journal of Cardiovascular Nursing ( 2017 ) 17 ( Supplement ), S71

Background: Dyslipidemia management situation in patients with high risk and very high risk has been demonstrated very low, despite the wide use of statins.
Purpose: The aim of this study was to evaluate the efficacy and safety of combination therapy with simvastatin and fenofibrate in patients after coronary artery stenting.
Methods: A total of 153 patients after coronary artery stenting were randomly assigned to receive 10 mg simvastatin (n = 71) and a combination of 10 mg simvastatin plus 200 mg fenofibrate (n = 82) for 1 months. In order to evaluate the clinical effects on lipids-lowering, systemic inflammation response and clinical safety, the follow-up of all patients was carried out at day 10th and 30th after treatment.
Results: Combination treatment was more effective in normalizing lipid profile than monotherapy. The level of low-density lipoprotein cholesterol (LDL-C) in combination group and statins group was 1.89 ± 0.42 and 2.34 ± 0.65 mmol/L at day 10th, 1.55 ± 0.31 and 1.96 ± 0.49 mmol/L at day 30th, respectively. The control rates of LDL-C level in the combination group and the statins group were 76% and 45% at day 30th, respectively. There was no significant improvement on high-density lipoprotein cholesterol (HDL-C) level during follow-up. The triglyceride (TG) levels were significantly reduced in both groups, while no obvious difference was observed between two groups. No significant difference on serum high-sensitivity C-reactive protein (hs-CRP) level between two groups was observed. Moreover, we did not observe any significant correlation between serum lipids levels and serum hs-CRP level during follow-up. The liver dysfunction and muscle related side effects (MRSE), creatine kinase (CK) and myopathy were not observed in both groups.
Conclusion: The results of this study demonstrated that combination therapy with fenofibrate and simvastatin is more effective than monotherapy in patients after coronary artery revasculirisation, and is generally safe and well tolerated.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are